Kate Therapeutics
Lydia Fang is a skilled Associate Scientist with experience in process development, vector development, and bio-assays for clinical trials. Lydia holds a Master of Science in Biotechnology from Harvard University and a Bachelor of Science in Cell/Cellular and Molecular Biology from the University of Illinois Urbana-Champaign.
Kate Therapeutics
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.